In Silico Pharmacology

, 5:13 | Cite as

In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies

  • M. C. Sharma
  • S. Jain
  • R. Sharma
Original Research


To explore the relationship between the structures of substituted pyrrolidine derivatives and their inhibition of dipeptidyl peptidase IV inhibitors. The QSAR, including CoMFA, CoMSIA and HQSAR, were applied to identify the key structures impacting their inhibitory potencies. The CoMFA, CoMSIA and HQSAR with cross-validated correlation coefficient (q2) value of 0.727, 0.870 and 0.939 and r2 value of 0.973, 0.981 and 0.949. Based on the structure–activity relationship revealed by the present study, we have designed a set of novel dipeptidyl peptidase IV inhibitors that showed excellent potencies in the developed models. Thus, our results allowed us to design new derivatives with desired activities.


Pyrrolidine CoMFA CoMSIA HQSAR Docking Dipeptidyl peptidase IV 



The authors are thankful to Head, School of Pharmacy, DAVV Indore for providing necessary facilities. Shikha Jain thanks the All India Council for Technical Education (AICTE), New Delhi, India, for the financial support for this research.


  1. Ai Y, Wang ST, Sun PH, Song FJ (2011) Combined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as aurora a kinase inhibitors. Int J Mol Sci 12:1605–1624CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bush BL, Nachbar RB Jr (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 7:587–619CrossRefPubMedGoogle Scholar
  3. Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110(18):5959–5967CrossRefPubMedGoogle Scholar
  4. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Meta 80(3):952–957Google Scholar
  5. Defronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L (2008) Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloricin take: a randomized, cross-over study. Curr Med Res Opin 24:2943–2952CrossRefPubMedGoogle Scholar
  6. Fukushima H, Hiratate A, Takahashi M, Mikami A, Saito-Hori M, Munetomo E, Kitano K, Chonan S, Saito H, Suzuki A, Takaoka Y, Yamamoto K (2008) Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem 16(7):4093–4106CrossRefPubMedGoogle Scholar
  7. Gupta AK, Saxena AK (2011) 3D-QSAR CoMFA and CoMSIA studies on a set of diverse-adrenergic receptor antagonists. Med Chem Res 20:1455–1464CrossRefGoogle Scholar
  8. Gupta AK, Bhunia SS, Balaramnavar VM, Saxena AK (2011) Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors. SAR QSAR Environ Res 22(3):239–263CrossRefPubMedGoogle Scholar
  9. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP (2007) Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 23:1329–1339CrossRefPubMedGoogle Scholar
  10. Havale SH, Pal M (2009) Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem 17:1783–1802CrossRefPubMedGoogle Scholar
  11. Holst JJ (1999) Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Met 10(6):229–235CrossRefGoogle Scholar
  12. Holst JJ (2005) Therapy of type 2 diabetes mellitus based on the actions of glucagonlike peptide-1. Diabetes Metab Res Rev 18(6):430–441CrossRefGoogle Scholar
  13. Hui H, Zhao X, Perfetti R (2005) Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev 21(4):313–331CrossRefPubMedGoogle Scholar
  14. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130–4146CrossRefPubMedGoogle Scholar
  15. Peters JU, Weber S, Kritter S, Weiss P, Wallier A, Boehringer M, Hennig M, Kuhn B, Loeffler BM (2004) Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. Bioorg Med Chem Lett 14(6):1491–1493CrossRefPubMedGoogle Scholar
  16. Ping L, Chen WN, Chen WM (2011) Molecular modeling studies on imidazo [4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches. Eur J Med Chem 46:77–94CrossRefGoogle Scholar
  17. Pirhadi S, Ghasemi JB (2010) 3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA. Eur J Med Chem 45:4897–4903CrossRefPubMedGoogle Scholar
  18. Saqib U, Siddiqi MI (2009) 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidylpeptidase-IV as anti-diabetic agents. SAR QSAR Environ Res 20:519–535CrossRefPubMedGoogle Scholar
  19. Sridhara J, Foroozesha M, Stevens CLK (2011) A QSAR models of cytochrome P450 enzyme 1A2 inhibitors using CoMFA, CoMSIA and HQSAR. SAR QSAR Environ Res 22:681–697CrossRefGoogle Scholar
  20. SYBYL6.9, Tripos Inc., St. Louis, MO, USAGoogle Scholar
  21. Turner R, Cull C, Holman R (1996) United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136–145CrossRefPubMedGoogle Scholar
  22. UK Prospective Diabetes Study (UKPDS) Group (1998a) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefGoogle Scholar
  23. UK Prospective Diabetes Study (UKPDS) Group (1998b) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRefGoogle Scholar
  24. Viswanadhan VN, Ghose AK, Revankar RG, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29(3):163–172CrossRefGoogle Scholar
  25. Zeng J, Liu G, Tang Y, Jiang H (2007) 3D-QSAR studies on fluoro- pyrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA. J Mol Model 13:993–1000CrossRefPubMedGoogle Scholar
  26. Zhao X, Chen M, Huang B, Ji H, Yuan M (2011) Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) studies on a(1A)-adrenergic receptor antagonists based on pharmacophore molecular alignment. Int J Mol Sci 12:7022–7037CrossRefPubMedPubMedCentralGoogle Scholar
  27. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.School of PharmacyDevi Ahilya UniversityIndoreIndia

Personalised recommendations